Logo image of COLL

COLLEGIUM PHARMACEUTICAL INC (COLL) Stock Price, Quote, News and Overview

NASDAQ:COLL - Nasdaq - US19459J1043 - Common Stock - Currency: USD

30.35  -0.16 (-0.52%)

After market: 30.35 0 (0%)

COLL Quote, Performance and Key Statistics

COLLEGIUM PHARMACEUTICAL INC

NASDAQ:COLL (7/3/2025, 1:48:23 PM)

After market: 30.35 0 (0%)

30.35

-0.16 (-0.52%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High42.29
52 Week Low23.23
Market Cap975.45M
Shares32.14M
Float31.57M
Yearly DividendN/A
Dividend YieldN/A
PE4.68
Fwd PE3.75
Earnings (Next)08-06 2025-08-06/amc
IPO05-07 2015-05-07


COLL short term performance overview.The bars show the price performance of COLL in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 2 4 6 8

COLL long term performance overview.The bars show the price performance of COLL in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 40 60

The current stock price of COLL is 30.35 USD. In the past month the price increased by 4.38%. In the past year, price decreased by -5.19%.

COLLEGIUM PHARMACEUTICAL INC / COLL Daily stock chart

COLL Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 56.73 739.87B
JNJ JOHNSON & JOHNSON 15.52 375.37B
NVO NOVO-NORDISK A/S-SPONS ADR 18.69 307.35B
NVS NOVARTIS AG-SPONSORED ADR 14.67 240.76B
AZN ASTRAZENECA PLC-SPONS ADR 15.78 215.32B
MRK MERCK & CO. INC. 10.39 203.22B
PFE PFIZER INC 7.91 144.29B
SNY SANOFI-ADR 10.55 117.55B
BMY BRISTOL-MYERS SQUIBB CO 6.39 95.49B
GSK GSK PLC-SPON ADR 8.48 77.37B
ZTS ZOETIS INC 26.44 70.87B
TAK TAKEDA PHARMACEUTIC-SP ADR 63.92 47.92B

About COLL

Company Profile

COLL logo image Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. The company is headquartered in Stoughton, Massachusetts and currently employs 357 full-time employees. The company went IPO on 2015-05-07. The firm has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic.

Company Info

COLLEGIUM PHARMACEUTICAL INC

100 Technology Center Dr

Stoughton MASSACHUSETTS 02072 US

CEO: Joseph Ciaffoni

Employees: 357

COLL Company Website

COLL Investor Relations

Phone: 17817133699

COLLEGIUM PHARMACEUTICAL INC / COLL FAQ

What is the stock price of COLLEGIUM PHARMACEUTICAL INC today?

The current stock price of COLL is 30.35 USD. The price decreased by -0.52% in the last trading session.


What is the ticker symbol for COLLEGIUM PHARMACEUTICAL INC stock?

The exchange symbol of COLLEGIUM PHARMACEUTICAL INC is COLL and it is listed on the Nasdaq exchange.


On which exchange is COLL stock listed?

COLL stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for COLLEGIUM PHARMACEUTICAL INC stock?

11 analysts have analysed COLL and the average price target is 43.86 USD. This implies a price increase of 44.51% is expected in the next year compared to the current price of 30.35. Check the COLLEGIUM PHARMACEUTICAL INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is COLLEGIUM PHARMACEUTICAL INC worth?

COLLEGIUM PHARMACEUTICAL INC (COLL) has a market capitalization of 975.45M USD. This makes COLL a Small Cap stock.


How many employees does COLLEGIUM PHARMACEUTICAL INC have?

COLLEGIUM PHARMACEUTICAL INC (COLL) currently has 357 employees.


What are the support and resistance levels for COLLEGIUM PHARMACEUTICAL INC (COLL) stock?

COLLEGIUM PHARMACEUTICAL INC (COLL) has a support level at 29.91 and a resistance level at 29.99. Check the full technical report for a detailed analysis of COLL support and resistance levels.


Is COLLEGIUM PHARMACEUTICAL INC (COLL) expected to grow?

The Revenue of COLLEGIUM PHARMACEUTICAL INC (COLL) is expected to grow by 18.09% in the next year. Check the estimates tab for more information on the COLL EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy COLLEGIUM PHARMACEUTICAL INC (COLL) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does COLLEGIUM PHARMACEUTICAL INC (COLL) stock pay dividends?

COLL does not pay a dividend.


When does COLLEGIUM PHARMACEUTICAL INC (COLL) report earnings?

COLLEGIUM PHARMACEUTICAL INC (COLL) will report earnings on 2025-08-06, after the market close.


What is the Price/Earnings (PE) ratio of COLLEGIUM PHARMACEUTICAL INC (COLL)?

The PE ratio for COLLEGIUM PHARMACEUTICAL INC (COLL) is 4.68. This is based on the reported non-GAAP earnings per share of 6.49 and the current share price of 30.35 USD. Check the full fundamental report for a full analysis of the valuation metrics for COLL.


What is the Short Interest ratio of COLLEGIUM PHARMACEUTICAL INC (COLL) stock?

The outstanding short interest for COLLEGIUM PHARMACEUTICAL INC (COLL) is 15.26% of its float. Check the ownership tab for more information on the COLL short interest.


COLL Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to COLL. When comparing the yearly performance of all stocks, COLL is a bad performer in the overall market: 65.73% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

COLL Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to COLL. While COLL belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

COLL Financial Highlights

Over the last trailing twelve months COLL reported a non-GAAP Earnings per Share(EPS) of 6.49. The EPS increased by 106.69% compared to the year before.


Industry RankSector Rank
PM (TTM) 6.61%
ROA 2.69%
ROE 18.72%
Debt/Equity 3.3
Chartmill High Growth Momentum
EPS Q2Q%2.76%
Sales Q2Q%22.66%
EPS 1Y (TTM)106.69%
Revenue 1Y (TTM)17.18%

COLL Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 82% to COLL. The Buy consensus is the average rating of analysts ratings from 11 analysts.

For the next year, analysts expect an EPS growth of 23.61% and a revenue growth 18.09% for COLL


Ownership
Inst Owners116.69%
Ins Owners1.52%
Short Float %15.26%
Short Ratio16.18
Analysts
Analysts81.82
Price Target43.86 (44.51%)
EPS Next Y23.61%
Revenue Next Year18.09%